MNPR vs VRTX: Which Stock is Better?

Side-by-side comparison of Monopar Therapeutics and Vertex Pharmaceuticals Inc in 2026

Comparison Updated:

MNPR

Monopar Therapeutics

$70.32

VRTX

Vertex Pharmaceuticals Inc

$442.08

Key Metrics Comparison

MetricMNPRVRTXWinner
Market Cap$469.92M$113.35BVRTX
P/E RatioN/A31.15VRTX
EPS (TTM)$N/A$14.19VRTX
Revenue Growth0.0%0.1%VRTX
Gross Margin0.0%52.7%VRTX

Analyze MNPR

Full quant analysis

Analyze VRTX

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is MNPR or VRTX a better investment?

Comparing MNPR and VRTX: Monopar Therapeutics has a market cap of $469.92M while Vertex Pharmaceuticals Inc has $113.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between MNPR and VRTX?

MNPR (Monopar Therapeutics) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: MNPR or VRTX?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: MNPR or VRTX?

VRTX has higher revenue growth at 0.1% vs 0.0% for MNPR.

Which company is more profitable: MNPR or VRTX?

Vertex Pharmaceuticals Inc (VRTX) has higher gross margins at 52.7% compared to 0.0% for MNPR.

Which is the larger company: MNPR or VRTX?

Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $113.35B compared to $469.92M for MNPR.

Should I buy MNPR or VRTX in 2026?

Both MNPR and VRTX have investment merit. MNPR trades at $70.32 while VRTX trades at $442.08. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between MNPR and VRTX stock?

Key differences: Market Cap ($469.92M vs $113.35B), P/E Ratio (N/A vs 31.2x), Revenue Growth (0.0% vs 0.1%), Gross Margin (0.0% vs 52.7%).

Popular Stock Comparisons